2. 医学
  3. Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu

Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu

admin2013-11-30  263
问题     Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolution is based on the idea that the sicker people are, the more freedom they should have to try drugs that are not yet fully tested. For fifty years government policy has been driven by another idea; the fear that insufficiently tested medicines could cause deaths and injuries. The urgent needs of people infected with HIV, the AIDS virus, and the possibility of meeting them with new drugs have created a compelling countervailing force to the continuing concern with safety. As a result, government rules and practices have begun to change. Each step is controversial. But the shift has already gone far beyond AIDS. New ways are emerging for very sick people to try some experimental drugs before they are marketed. People with the most serious forms of heart disease, cancer, emphysema, Alzheimer’ s or Parkinson’ s disease, multiple sclerosis, epilepsy , diabetes, or other grave illnesses can request such drugs through their doctors and are likelier to get them than they would have been four years ago. " We’ ve been too rigid in not making life-saving drugs available to people who otherwise face certain death," says Representative Henry Wax-man, of California, who heads the subcommittee that considers changes in drug-approval policies. "It’ s true of AIDS, but it’ s also true of cancer and other life-threatening diseases. "
    For the first time, desperate patients have become a potent political force for making new medicines available quickly. People with AIDS and their advocates, younger and angrier than most heart-disease or cancer patients, are drawing on two decades of gay activists’ success in organizing to get what they want from politicians. At times they found themselves allied with Reagan Administration deregulators, scientists, industry representatives, FDA staff members, and sympathetic members of Congress. They organized their own clinical trials and searched out promising drugs here and abroad. The result is a familiar Washington story; a crisis—AIDS—helped crystallize an informal coalition for reform.
    AIDS gave new power to old complaints. As early as the 1970s the drug industry and some independent authorities worried that the Food and Drug Administration’ s testing requirements were so demanding that new drugs were being unreasonably delayed. Beginning in 1972, several studies indicated that the United States had lost its lead in marketing new medicines and that breakthrough drugs, those that show new promise in treating serious or life—threatening diseases—had come to be available much sooner in other countries. Two high-level commissions urged the early release of breakthrough drugs. So did the Carter Administration, but the legislation it proposed died in Congress. Complaints were compounded by growing concern that "if we didn’ t streamline policies, red tape would be an obstacle to the development of the biotechnology revolution," as Frank E. Young, who was the head of the FDA from 1984 to 1989, put it in an interview with me.
    Young was a key figure in the overhaul of the FDA’ s policies. A pioneer in biotechnology and a former dean of the University of Rochester’ s medical school, he came to Washington with an agenda and headed the agency for five and a half years—longer than anyone else has since the 1960s. Young took the FDA job to help introduce new medicines created by biotechnology—whose promise he had seen in his own gene-cloning lab and to get experimental medicines to desperately ill people more quickly. He had seen people die waiting for new medicines because " they were in the wrong place at the wrong time," he said. That is now changing.  
According to the passage, patients who are gravely ill______.
选项 A、can get experimental drugs more quickly than ever before
B、are still unable to get experimental drugs because of government strict policies
C、can’ t afford some expensive experimental drugs
D、refuse to be treated with experimental drugs
答案A
解析 文章第一段指出“People with the most serious…been four years ago”，即患有严重疾病的人可通过医生得到实验药物，并且比四年前更容易获得，选项A正确。
转载请注明原文地址:https://kaotiyun.com/show/utU3777K
本试题收录于： 医学博士外语题库考研分类
0

医学博士外语

考研

相关试题推荐
随机试题
最新回复(0)